Home JournalsJournal Details

eISSN: 2468-1253 CAS Zone: Medicine (Zone 1) Emerging Zone: Medicine (Zone 1)

Lancet Gastroenterology & Hepatology

Abbr. LANCET GASTROENTEROL

39.1

Latest IF

Recent Articles

Liver stiffness dynamics in European populations – Authors’ reply

Pustjens J, Ginès P, Brouwer W · Vol 11(10): 872-873

2026-09-02

From viral clearance to cancer prevention: the next phase of hepatitis elimination

AbdAllah M, Abdel-Razek W, Hassany M · Vol 11(10): 873-874

2026-09-02

Cyclosporiasis and CDC cuts: the perfect storm

The Lancet Gastroenterology & Hepatology · Vol 11(10): 863

2026-09-02

Correction to Lancet Gastroenterol Hepatol 2026; 11: 627–44

Vol 11(10): e11

2026-09-02

Liver stiffness dynamics in European populations

André-Dumont S, Lanthier N · Vol 11(10): 872

2026-09-02

Blood-based CRC screening: closer, but not there yet

The Lancet Gastroenterology & Hepatology · Vol 11(10): 863

2026-09-02

Prevention of colorectal cancer through screening for advanced precancerous lesions: are blood-based tests the answer?

Winter J, Symonds E · Vol 11(10): 864-865

2026-08-10

A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study

Mannucci A, Xu C, Balaguer F et al · Vol 11(10): 897-907

2026-08-10

Combination therapy in metabolic dysfunction-associated steatohepatitis

Shibolet O, Katchman H · Vol 11(9): 732-733

2026-08-05

Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis – Authors' reply

Jalan R, Patel V, Shoaie S · Vol 11(9): 758

2026-08-05

Correction to Lancet Gastroenterol Hepatol 2026; published online July 16. https://doi.org/10.1016/S2468-1253(26)00163-9

Vol 11(10): e11

2026-07-31

WHO global hepatitis report 2026: guiding global action for elimination

Lesi O, Faini D, Law I et al · Vol 11(10): 865-867

2026-07-27

Launch of the Africa CDC toolkit for hepatitis B: bringing care closer to people in Africa

Stockdale A, Ndow G, Adda D et al · Vol 11(10): 867-869

2026-07-27

The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial

Noureddin M, Dunn W, Patil R et al · Vol 11(10): 887-896

2026-07-21

Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial

Hüneburg R, van Bokhorst Q, Pellisé M et al · Vol 11(10): 875-886

2026-07-16

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Reinisch W, Stepek D, Kempinski R et al · Vol 11(9): 775-785

2026-07-16

Barrier restoration as a therapeutic strategy for disorders of gut–brain interaction

Britton T, Grover M · Vol 11(10): 908-924

2026-07-07

Bowel endometriosis: from pathogenesis to clinical management

Barra F, Giannini E, Centurioni M et al · Vol 11(10): 925-942

2026-07-03

The central role of primary care in liver health

Brierley R, Thomas H · Vol 11(9): 733-734

2026-07-01

Propelling MASLD trials into the era of non-invasive tests

Lian L, Liu W, Li W et al · Vol 11(10): 869-871

2026-06-12

Journal Info

Abbr.

LANCET GASTROENTEROL

CAS Zone

Medicine (Zone 1) · Top

Emerging Zone

Medicine (Zone 1) · Non-Top

Sub-categories

GASTROENTEROLOGY & HEPATOLOGYZone 1

Emerging Categories

GASTROENTEROLOGY & HEPATOLOGYZone 1

Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.

Business Email

E-mail: product@genelibs.com